| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Cyclo(Pro-Val) targets Gram-positive bacteria, including Bacillus subtilis and Staphylococcus aureus. It demonstrates selective antibacterial activity against Gram-positive bacteria. The compound has been studied for its potential biological activities, including antimicrobial, anti-inflammatory, and antioxidant properties. It also exhibits weak antitumor activity.
|
|---|---|
| ln Vitro |
Cyclo(Pro-Val) (10, 20, and 30 μg/ml, 48 hours)led to 65%, 73%, and 80% mortality of suspended cells, respectively.
In vitro, Cyclo(Pro-Val) demonstrates cytotoxicity, moderate antifungal activity, and weak antitumor activity. It inhibits the growth of Bacillus subtilis with a minimal inhibitory concentration (MIC) of 0.8 g/L. It shows dose-dependent cytotoxicity in suspension cell assays. At concentrations of 10, 20, and 30 μg/mL for 48 hours, it causes suspension cell death rates of 65%, 73%, and 80%, respectively. |
| ln Vivo |
In vivo activity data for Cyclo(Pro-Val) are limited. The compound has been studied for its potential biological activities, including antimicrobial, anti-inflammatory, and antioxidant properties. However, specific animal model studies have not been detailed in the available literature. Further investigation is needed to confirm its systemic efficacy.
|
| Enzyme Assay |
Specific protocols for enzyme or receptor binding assays have not been established for Cyclo(Pro-Val). Antimicrobial activity is assessed using standard broth microdilution methods to determine MIC values. Cytotoxicity is evaluated using standard cell viability assays such as MTT or SRB.
|
| Cell Assay |
Cell-based assays for Cyclo(Pro-Val) involve treating suspension cells with the compound at concentrations of 10, 20, and 30 μg/mL for 48 hours. Cell death rates are measured to assess cytotoxicity. Antimicrobial activity can be evaluated in bacterial cultures by measuring growth inhibition.
|
| Animal Protocol |
In vivo animal protocols for Cyclo(Pro-Val) have not been established. For related antimicrobial peptides, standard models involve administering the compound to infected animals and monitoring survival and bacterial load. Specific protocols for this compound are not documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Cyclo(Pro-Val) are not extensively reported. The compound has a molecular weight of 196.25 and a molecular formula of C10H16N2O2. It is stored as a powder at -20°C for up to 3 years and in solvent at -80°C for up to 6 months. As a cyclic dipeptide, it may have improved stability compared to linear peptides.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cyclo(Pro-Val) are limited. The compound exhibits dose-dependent cytotoxicity in suspension cell assays. As a research-use-only compound, it has not undergone formal safety assessment. Standard laboratory precautions should be observed when handling the compound.
|
| References | |
| Additional Infomation |
Cyclic (D-valine-L-proline) is an oxygen- and nitrogen-containing organic compound. Functionally, it is associated with α-amino acids. Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-3-(1-methylethyl)- has been reported in Streptomyces niger, Aspergillus fumigatus, and other organisms with relevant data.
Cyclo(Pro-Val) is a research-use-only compound. It is a cyclic dipeptide obtained from marine fungi. It demonstrates moderate antifungal activity, antibacterial activity against Bacillus subtilis with an MIC of 0.8 g/L, and dose-dependent cytotoxicity. It exhibits selective antibacterial activity against Gram-positive bacteria. It can serve as a building block for more complex peptide sequences in drug design. |
| Molecular Formula |
C10H16N2O2
|
|---|---|
| Molecular Weight |
196.25
|
| Exact Mass |
196.121
|
| CAS # |
5654-87-5
|
| Related CAS # |
(R,R)-Cyclo(Pro-Val); Cyclo(Pro-Val)-d4; Cyclo(Pro-Val); 5654-87-5
|
| PubChem CID |
98951
|
| Appearance |
White to off-white solid
|
| Density |
1.17g/cm3
|
| Boiling Point |
420.7ºC at 760 mmHg
|
| Flash Point |
208.2ºC
|
| Index of Refraction |
1.535
|
| Source |
Originated from microorganisms: Pseudomonas fluorescens GcM5-1A
|
| LogP |
0.398
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
14
|
| Complexity |
275
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(C(C)C)N([H])C(C2CCCN21)=O
|
| InChi Key |
XLUAWXQORJEMBD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H16N2O2/c1-6(2)8-10(14)12-5-3-4-7(12)9(13)11-8/h6-8H,3-5H2,1-2H3,(H,11,13)
|
| Chemical Name |
3-propan-2-yl-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~254.8 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (6.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0955 mL | 25.4777 mL | 50.9554 mL | |
| 5 mM | 1.0191 mL | 5.0955 mL | 10.1911 mL | |
| 10 mM | 0.5096 mL | 2.5478 mL | 5.0955 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
